Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | VHL | P40337 | 3/20 | 0.42 |
| ▸ | ELOC | Q15369 | 2/20 | 0.42 |
| ▸ | ELOB | Q15370 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292790 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL3371956 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL13318866 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL20120875 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL8015855 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL20120873 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL8253158 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL10347003 | 0.90 | PEPD (0.47) | ELANEVHLELOCELOBMMP2 | |
| SCHEMBL13744721 | 0.90 | PEPD (0.47) | ELANEVHLELOCELOBMMP2 | |
| SCHEMBL13817413 | 0.89 | ANPEP (0.56) | ELANEVHLELOCELOBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4606799-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2025-08-27 | — | — | EP | disclosed |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
| WO-2008064066-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008008776-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| WO-2007089618-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006122188-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2005051410-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | ELANE 3760/4885ALDH1A1 1922/4885VHL 1016/4885 |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | ELANE 3423/4885ALDH1A1 3337/4885VHL 30/4885 |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ELANE 1285/4885ALDH1A1 623/4885VHL 3152/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ELANE 3586/4885ALDH1A1 4101/4885VHL 208/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ELANE 4217/4885ALDH1A1 3566/4885VHL 20/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | ELANE 2244/4885ALDH1A1 4621/4885VHL 242/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | ELANE 2323/4885ALDH1A1 4714/4885VHL 333/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | ELANE 1503/4885ALDH1A1 2777/4885VHL 2/4885 |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | PREP, PPIL4, PPID | ELANE 2528/4885ALDH1A1 2011/4885VHL 1970/4885 |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | ELANE 3802/4885ALDH1A1 2981/4885VHL 31/4885 |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | ELANE 1405/4885ALDH1A1 3365/4885VHL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.